Adicet Bio
ACET
56 hedge funds and large institutions have $52.8M invested in Adicet Bio in 2026 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
21% more capital invested
Capital invested by funds: $43.7M → $52.8M (+$9.13M)
14% more funds holding
Funds holding: 49 → 56 (+7)
1.44% less ownership
Funds ownership: 66.8% → 65.36% (-1.4%)
79% less call options, than puts
Call options by funds: $93K | Put options by funds: $453K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.54M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$677K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$626K |
| 4 |
Two Sigma Investments
New York
|
+$423K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$401K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$2.13M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.97M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.7M |
| 4 |
O
OrbiMed
New York
|
-$1.44M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$367K |
ACET Hedge Fund Activity: Q2 2026 in Review
56 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q2 2026, worth a combined $52.8M — up 21% from $43.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ACET positions and 6 closed out — a net gain of 7 holders — while 18 added to existing stakes and 9 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $1.54M. The largest seller was Woodline Partners, exiting entirely with an estimated $2.13M sold.
- 56 institutional investors held Adicet Bio (ACET) as of Q2 2026, up from 49 in Q1 2026.
- Funds reported $52.8M of Adicet Bio stock for Q2 2026, up 21% quarter-over-quarter.
- 13 funds opened new Adicet Bio positions in Q2 2026 and 6 closed out, a net change of +7 holders.
- The largest Adicet Bio buyer in Q2 2026 was Schonfeld Strategic Advisors, an estimated $1.54M added.
- The largest Adicet Bio seller in Q2 2026 was Woodline Partners, an estimated $2.13M sold.
Based on aggregated 13F filings for Q2 2026.